Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 12:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 2,099 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Injectable saline Clear all
Completed Phase 1Phase 2 Interventional Results available

The Transendocardial Autologous Cells (hMSC or hBMC) in Ischemic Heart Failure Trial (TAC-HFT)

NCT00768066
View directory record Official record
Conditions
Stem Cell Transplantation, Ventricular Dysfunction, Left
Interventions
Autologous human mesenchymal cells (hMSCs), Autologous human bone marrow cells (hBMCs), Placebo
Biological
Lead sponsor
University of Miami
Other
Eligibility
21 Years to 90 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Dec 14, 2015 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Immunogenicity Study of Self-Amplifying RNA Pandemic Influenza Vaccine in Adults

NCT06602531
View directory record Official record
Conditions
Influenza, Human
Interventions
ARCT-2304, Control vaccine younger adults, Control vaccine older adults, Placebo Vaccine
Biological · Other
Lead sponsor
Arcturus Therapeutics, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
212 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
4
States / cities
La Mesa, California • San Bernardino, California • Longmont, Colorado + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Not applicable Interventional

Platelet Rich Plasma (PRP) for Vulvar Lichen Sclerosus

NCT03045172
View directory record Official record
Conditions
Lichen Sclerosus of Vulva
Interventions
Platelet Rich Plasma, Placebo
Biological · Drug
Lead sponsor
Center for Vulvovaginal Disorders
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Oct 25, 2018 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

The Effect of Liposomal Bupivacaine on Post Operative Pain and Narcotic Use After Bariatric Surgery

NCT03196505
View directory record Official record
Conditions
Bariatric Surgery Candidate, Pain, Postoperative
Interventions
Exparel 266 MG Per 20 ML Injection, Bupivacaine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 65 Years
Enrollment
231 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
Fresno, California
Source: ClinicalTrials.gov public record
Updated Nov 25, 2020 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

NCT05285137
View directory record Official record
Conditions
Healthy
Interventions
CD388 Injection, Saline placebo
Combination Product · Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Chiron Corp HCV E1/E2 Vaccine

NCT00500747
View directory record Official record
Conditions
Hepatitis C
Interventions
HCV E1E2/MF59, Placebo
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 45 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2005
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 10, 2011 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Results available

Clofarabine Bone Marrow Cytoreduction

NCT00724009
View directory record Official record
Conditions
Leukemia
Interventions
Clofarabine
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 18, 2014 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 1 Interventional

Muscle Anabolic Interventions to Accelerate Recovery From Hospitalization in Geriatric Patients

NCT02990533
View directory record Official record
Conditions
Aging
Interventions
Testosterone, Protein Supplement, Placebo Injection, Placebo supplement
Drug · Dietary Supplement · Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
65 Years and older
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Results available

Safety and Immunogenicity of a Trivalent Group B Streptococcus Vaccine in Healthy Pregnant Women

NCT02046148
View directory record Official record
Conditions
GBS Disease, Streptococcus Agalactiae
Interventions
GBS trivalent vaccine, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
6
States / cities
Aurora, Colorado • Baltimore, Maryland • Durham, North Carolina + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 29, 2020 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 3 Interventional Results available

Phase III Double-blind, Placebo-controlled Study of AZD7442 for Pre-exposure Prophylaxis of COVID-19 in Adult.

NCT04625725
View directory record Official record
Conditions
COVID-19
Interventions
AZD7442, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 120 Years
Enrollment
5,197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
60
States / cities
Birmingham, Alabama • Tempe, Arizona • Little Rock, Arkansas + 53 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2024 · Synced Oct 25, 2026, 12:31 AM EDT
Terminated Phase 4 Interventional Results available

Treating Patients With Aneurysmal SubArachnoid Hemorrhage (SAH) With Epoetin Alfa

NCT00626574
View directory record Official record
Conditions
Subarachnoid Hemorrhage
Interventions
Epoetin alfa, Saline
Drug
Lead sponsor
University of South Florida
Other
Eligibility
30 Years to 75 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2018 · Synced Oct 25, 2026, 12:31 AM EDT
Not yet recruiting Phase 3 Interventional

iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable Melanoma

NCT07815574
View directory record Official record
Conditions
Melanoma (Skin Cancer), Advanced Melanoma, Metastatic Melanoma, Skin Cancer
Interventions
iSCIB1+, Nivolumab & Ipilimumab, Placebo
Biological · Drug · Other
Lead sponsor
Scancell Ltd
Industry
Eligibility
18 Years and older
Enrollment
550 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 11, 2026 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetics of MP-3180 in Healthy Volunteers

NCT02098174
View directory record Official record
Conditions
Glomerular Filtration Rate, Acute Kidney Injury
Interventions
MP-3180, Iohexol comparator
Drug · Other
Lead sponsor
MediBeacon
Industry
Eligibility
22 Years and older
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 23, 2016 · Synced Oct 25, 2026, 12:31 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Phase 2/3 Study on the Efficacy and Safety of Mangaciclanol for Contrast-Enhanced MRI of CNS or Body in Adult Patients

NCT07472491
View directory record Official record
Conditions
Known or Highly Suspected Central Nervous System (CNS) Lesion, Known or Highly Suspected Body (Excluding CNS) Lesion
Interventions
Mangaciclanol, also known as GEH200486 Injection, 0.5 mmol/mL, MRI Scan, Gadobutrol
Drug · Diagnostic Test
Lead sponsor
GE Healthcare
Industry
Eligibility
18 Years and older
Enrollment
640 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Rochester, Minnesota • The Woodlands, Texas
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Oct 25, 2026, 12:31 AM EDT
Recruiting Phase 2Phase 3 Interventional

Use of Corticosteroid in Intraopertive Injections in Total Knee Replacement Surgery.

NCT07151417
View directory record Official record
Conditions
Knee Osteoarthritis, Musculoskeletal Disease, Surgery
Interventions
PAI, PAI + steroid, PAI + zilretta
Drug
Lead sponsor
Walter Reed National Military Medical Center
Federal
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 4 Interventional Results available

Bacteriostatic Saline as a Local Anesthetic in Minor Eyelid Procedures

NCT05294640
View directory record Official record
Conditions
Eyelid Tumor, Eyelid Bump, Eyelid Deformity, Eyelid Abscess, Eyelid Boil, Eyelid Papilloma, Anesthesia, Local, Ophthalmology
Interventions
0.9% Bacteriostatic Local Anesthetic Injection, 1% Lidocaine with 1:100,000 epinephrine Local Anesthetic Injection, Eyelid Lesion Removal
Drug · Procedure
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 110 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Jul 8, 2025 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Results available

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer

NCT03138720
View directory record Official record
Conditions
Resectable Pancreatic Cancer, Unresectable Pancreatic Cancer, Pancreatic Adenocarcinoma, Neoadjuvant Pancreatic Cancer
Interventions
Paclitaxel Protein Bound (Abraxane)
Drug
Lead sponsor
HonorHealth Research Institute
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2025
U.S. locations
1
States / cities
Scottsdale, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 25, 2026, 12:31 AM EDT
Recruiting Phase 2 Interventional

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

NCT07059091
View directory record Official record
Conditions
Chronic Obstructive Pulmonary Disease (COPD), Allergies
Interventions
Omalizumab (Xolair®), Sodium Chloride (NaCl) 0.9 %
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
40 Years and older
Enrollment
334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
23
States / cities
Birmingham, Alabama • Tucson, Arizona • San Francisco, California + 16 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2026 · Synced Oct 25, 2026, 12:31 AM EDT
Active, not recruiting Phase 3 Interventional

Use of Extended Release Triamcinolone in the Treatment of Rotator Cuff Disease

NCT04094298
View directory record Official record
Conditions
Rotator Cuff Tears, Rotator Cuff Tendinitis, Rotator Cuff Impingement, Injections, Glucocorticoids
Interventions
FX006 Injection
Drug
Lead sponsor
Northwell Health
Other
Eligibility
40 Years to 75 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Great Neck, New York
Source: ClinicalTrials.gov public record
Updated Dec 27, 2024 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Otherwise Healthy Participants With High Low-density Lipoprotein (LDL) Cholesterol

NCT01618916
View directory record Official record
Conditions
Healthy Volunteers
Interventions
LY3015014, Placebo
Drug · Other
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
2
States / cities
Honolulu, Hawaii • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability, and Immunogenicity of CRV-101 in Healthy Adult Subjects

NCT03820414
View directory record Official record
Conditions
Herpes Zoster, Varicella Zoster
Interventions
CRV 101, Placebo
Biological
Lead sponsor
Curevo Inc
Industry
Eligibility
18 Years to 49 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Feb 11, 2021 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 1Phase 2 Interventional

The Impact of Botox® During Robotic Rehabilitation of the Wrist Following Stroke

NCT01088230
View directory record Official record
Conditions
Stroke
Interventions
Botox®, saline solution
Other
Lead sponsor
New York Presbyterian Hospital
Other
Eligibility
18 Years to 85 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 26, 2011 · Synced Oct 25, 2026, 12:31 AM EDT
Terminated Phase 2 Interventional Results available

Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis (LN)

NCT05540665
View directory record Official record
Conditions
Lupus Nephritis
Interventions
Daxdilimab, Placebo (Normal Saline)
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 80 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Birmingham, Alabama • San Dimas, California • Syracuse, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Oct 25, 2026, 12:31 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating the Safety, Tolerability, and Pharmacokinetics of an Investigational, Injectable HIV Medicine (GSK1265744) in HIV-Uninfected Adults

NCT02178800
View directory record Official record
Conditions
HIV Infections
Interventions
GSK1265744 Tablets, Injectable GSK1265744, Placebo for GSK1265744 Tablets, Injectable Placebo for GSK1265744
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
199 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2018
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • Washington D.C., District of Columbia + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Oct 25, 2026, 12:31 AM EDT